Over the last year or so, management has delivered significant progress in bringing its Affimer platform into to the commercial stage, across both therapeutics and diagnostic applications.
03 Oct 2018
Avacta Group - Maximising Affimer's potential across therapeutics and diagnostic applications
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group - Maximising Affimer's potential across therapeutics and diagnostic applications
Avacta Group PLC (AVCT:LON) | 49.8 -0.5 (-2.0%) | Mkt Cap: 174.4m
- Published:
03 Oct 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
4
Over the last year or so, management has delivered significant progress in bringing its Affimer platform into to the commercial stage, across both therapeutics and diagnostic applications.